Lenalidomide in Multiple Myeloma: NCT07764978 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Recruiting
Recruitment status
750
Planned enrollment
2029-01-11
Primary-completion proxy
Executive view
NCT07764978 evaluates Lenalidomide in Multiple Myeloma. The disclosed sponsor is AstraZeneca PLC, the design is Interventional, and the geographic footprint is United States, Japan, United Kingdom, Spain, Canada, Sweden, South Korea, Taiwan Province, Poland, Denmark, Brazil, Italy, France, Australia, Germany. The first listed primary endpoint is PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd., assessed over Up to 9 years..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07764978 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Myeloma landscape. Drug & Asset MCP drug_fetch was queried for Lenalidomide, while Company & Deal Intelligence MCP organization_fetch was queried for AstraZeneca PLC.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07764978 | Lenalidomide | Phase 3 / Recruiting | AstraZeneca PLC | United States, Japan, United Kingdom, Spain, Canada, Sweden, South Korea, Taiwan Province, Poland, Denmark, Brazil, Italy, France, Australia, Germany | PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction fo… Up to 9 years. | 2029-01-11 |
| NCT07811986 | Dexamethasone Sodium Phosphate | Phase 2 / Not yet recruiting | Sponsor not reported | China | Overall Response Rate (ORR) From the first dose to the end of Cycle 24 (each cycle is 28 days). | 2027-12-31 |
| NCT07809594 | CS1-targeted autologous CAR-T cells (Hematology Hospital of Chinese Academy of Medical Sciences) | Phase 1 / Active, not recruiting | Hematology Hospital of Chinese Academy of Medical Sciences | China | Number of Participants With Dose-Limiting Toxicities (DLTs) Within 28 Days After Autologous CS1 CAR-T Cell Infusion From the first CS1 CAR-T cell infusion through Day 28 after the first… | 2025-07-21 |
| NCT07802717 | VV169 | Phase 1 / Not yet recruiting | Vyriad, Inc. | United States | Safety and tolerability of VV169 and determine the maximum tolerated dose 2 years | 2027-08-31 |
| NCT07764861 | Daratumumab | Phase 2 / Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | China | MRD（ Minimal Residue Disease) negativity rate at 24 weeks 24weeks | 2026-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07764978 is a Phase 3, recruiting study with 750 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd.” over “Up to 9 years..” The retrieved endpoint description is: PFS: defined as time from randomisation until progression according to IMWG 2016 criteria as assessed by BICR, or death due to any cause, whichever occurs first..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 750 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Lenalidomide, Isatuximab-IRFC, Daratumumab as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Multiple Myeloma. These records do not establish direct evidence for NCT07764978 unless the registration number matches.
MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions
Phase 2; n=16; ORR = 75 percentage of participants (90% Confidence Interval, 47.3 - 92.8) Source: https://clinicaltrials.gov/ct2/show/results/NCT06390852
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapse…
Phase 3; n=154; PFS(Median) = 6.34 month (95% Confidence Interval, 5.55 - 11.79); PFS(Median) = 8.11 month (95% Confidence Interval, 6.28 - 11.99) Source: https://clinicaltrials.gov/ct2/show/results/NCT04939142
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Phase 1; n=324; AE(grade 3 or 4) = 59.6 % Source: https://pubmed.ncbi.nlm.nih.gov/42487061/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “Lenalidomide.” The report therefore avoids inferring modality, target or global development stage from the name alone.
AstraZeneca PLC is indexed in United Kingdom with the website http://www.astrazeneca.com. AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. The record lists 352 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Lenalidomide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07764978
Protocol source: https://clinicaltrials.gov/study/NCT07764978
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Lenalidomide in Multiple Myeloma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd. and 2029-01-11 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
